Consensus Intellia Therapeutics, Inc.

Equities

NTLA

US45826J1051

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-15 pm EDT			5-day change	1st Jan Change
22.92 ^USD	-5.56%		-9.41%	-24.83%

Mar. 25	Intellia Therapeutics Ends Development Agreement With Regeneron Pharmaceuticals	MT
Mar. 22	Intellia Therapeutics Ends Development Agreement With Regeneron Pharmaceuticals	MT

Evolution of the average Target Price on Intellia Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

830.AqUo2_uT37KrhnPRb2cjsFVy-qFSgiL1lozEm1GGAeQ.SNNekrjxvOfhzjSoOjNLiQoTo-hmsxCQ8c2w3R22RaZ2zGz2qqfr-cPFEA~1cb7cfa5ba243ab9e2f30ff5d339651c

Analyst Recommendations on Intellia Therapeutics, Inc.

Intellia Therapeutics Ends Development Agreement With Regeneron Pharmaceuticals	Mar. 25	MT
Intellia Therapeutics Ends Development Agreement With Regeneron Pharmaceuticals	Mar. 22	MT
Intellia Therapeutics Ends Co-Development Agreement With Regeneron	Mar. 22	DJ
Canaccord Genuity Adjusts Price Target on Intellia Therapeutics to $73 From $72, Maintains Buy Rating	Feb. 23	MT
Wolfe Research Starts Intellia Therapeutics With Peer Perform Rating	Feb. 15	MT
Morgan Stanley Adjusts Intellia Therapeutics' Price Target to $85 From $90, Keeps Overweight Rating	Nov. 13	MT
Oppenheimer Slashes Price Target on Intellia Therapeutics to $70 From $80, Maintains Outperform Rating	Nov. 13	MT
Goldman Sachs Adjusts Price Target on Intellia Therapeutics to $136 From $157, Maintains Buy Rating	Nov. 10	MT
RBC Cuts Price Target on Intellia Therapeutics to $70 From $80, Keeps Outperform, Speculative Risk	Nov. 10	MT
Wedbush Lowers Intellia Therapeutics' Price Target to $29 From $45, Maintains Neutral Rating	Nov. 10	MT
Canaccord Genuity Adjusts Price Target on Intellia Therapeutics to $65 From $66, Maintains Buy Rating	23-08-07	MT
Barclays Adjusts Intellia Therapeutics Price Target to $90 From $148, Maintains Overweight Rating	23-08-04	MT
RBC Cuts Intellia Therapeutics' Price Target to $90 From $100, Keeps Outperform Speculative Risk Rating	23-07-07	MT
Chardan Trims Price Target on Intellia Therapeutics to $107 From $111, Maintains Buy Rating	23-06-13	MT
Citigroup Adjusts Price Target on Intellia Therapeutics to $44 From $39, Maintains Neutral Rating	23-05-08	MT
Morgan Stanley Adjusts Price Target on Intellia Therapeutics to $86 From $83, Maintains Overweight Rating	23-05-08	MT
Oppenheimer Adjusts Intellia Therapeutics Price Target to $90 From $93, Maintains Outperform Rating	23-05-08	MT
BMO Capital Adjusts Price Target on Intellia Therapeutics to $64 From $57, Maintains Outperform Rating	23-05-05	MT
Raymond James Adjusts Price Target on Intellia Therapeutics to $78 From $94, Maintains Outperform Rating	23-05-05	MT
Canaccord Genuity Starts Intellia Therapeutics at Buy With $66 Price Target	23-04-13	MT
RBC Capital Adjusts Intellia Therapeutics Price Target to $100 From $120, Maintains Outperform - Speculative Risk Rating	23-04-06	MT
JPMorgan Cuts Intellia Therapeutics' Price Target to $79 From $82, Keeps Overweight Rating	23-03-31	MT
Bernstein Initiates Intellia Therapeutics at Outperform With $54 Price Target	23-03-21	MT
BMO Capital Upgrades Intellia Therapeutics to Outperform From Market Perform, Adjusts Price Target to $57 From $54	23-03-14	MT
Credit Suisse Lowers Intellia Therapeutics' Price Target to $76 From $88, Keeps Outperform Rating	23-02-24	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

24.27 USD

Average target price

71.12 USD

Spread / Average Target

+193.04%

High Price Target

144 USD

Spread / Highest target

+493.33%

Low Price Target

24 USD

Spread / Lowest Target

-1.11%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Intellia Therapeutics, Inc.

Canaccord Genuity
Wolfe Research
Morgan Stanley
Oppenheimer
Goldman Sachs
RBC Capital Markets
Wedbush
Barclays
Chardan Research
Citigroup
BMO Capital
Raymond James
JPMorgan Chase
Bernstein
Baird
Credit Suisse
EF Hutton
Cantor Fitzgerald
SVB Securities LLC
JMP Securities
Wells Fargo Securities
Piper Sandler
BofA Securities
Guggenheim
Brookline Capital Markets
William Blair & Co.
Cowen
HC Wainwright
Stifel Nicolaus
Chardan
Truist Securities
Roth Capital Partners
Jefferies & Co.

Ratings for Intellia Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar